Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents

NCT01239485 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01239485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01239485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents
Lead sponsor
Seoul National University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2010
Completion date
December 31, 2013
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia